<DOC>
	<DOCNO>NCT00353717</DOCNO>
	<brief_summary>Basal like breast carcinoma Her2 , estrogen receptor ( ER ) progesterone receptor ( PR ) negative breast cancer . It notable high level epidermal growth factor receptor ( EGFR ) expression tumor subtype . Thus investigator want combine use anti EGFR therapy form Erbitux ( cetuximab ) widely use weekly taxol chemotherapy treatment woman . This small phase I/II study .</brief_summary>
	<brief_title>Combined Treatment Cetuximab Paclitaxel Basal Like Breast Carcinoma</brief_title>
	<detailed_description>Basal like breast carcinoma Her2 , ER PR negative breast cancer . It notable high percentage EGFR expression tumor subtype.Weekly taxol ( paclitaxel ) widely use breast cancer patient metastatic disease . Erbitux ( cetuximab ) monoclonal antibody show ability enhance activity chemotherapy colon carcinoma . Thus want combine use anti EGFR therapy form Erbitux ( cetuximab ) widely use weekly taxol chemotherapy treatment woman basal like breast carcinoma . This small phase II study hopefully provide initial data general tolerability response rate combination disease . Furthermore , pathologic analysis use try assess relation response presence immunohistochemical marker EGFR expression .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients metastatic breast carcinoma basal like subtype available biopsy analysis ECOG PS 2 less Pregnancy BUN , blood creatinine , AST , ALT &gt; X3 upper limit normal More previous 2 chemotherapy line metastatic setting use previous inhibitor EGFR</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>breast</keyword>
	<keyword>basal like</keyword>
	<keyword>carcinoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>EGFR</keyword>
</DOC>